| Name | Title | Contact Details |
|---|
Cyagra Inc is a Elizabethtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
General Automation Lab Technologies (GALT), a San Francisco-based life science company, is developing advanced products to help researchers and companies cultivate and study bacteria and other microbes.
Threshold Pharmaceuticals, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alfa Wassermann, Inc. is a West Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.